Quote | Ocuphire Pharma Inc Com (NASDAQ:OCUP)
Last: | $1.54 |
---|---|
Change Percent: | 0.0% |
Open: | $1.51 |
Close: | $1.54 |
High: | $1.58 |
Low: | $1.51 |
Volume: | 140,451 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
News | Ocuphire Pharma Inc Com (NASDAQ:OCUP)
FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that Daniel Su, ...
LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire’s Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for t...
Message Board Posts | Ocuphire Pharma Inc Com (NASDAQ:OCUP)
Subject | By | Source | When |
---|---|---|---|
skip | Dr_Vonschellan | investorshub | 11/29/2022 7:28:47 PM |
$OCUP CompanyOverview | conix | investorshub | 11/23/2022 4:10:05 PM |
If it wasn't for the election stuff, this | KOmani | investorshub | 11/08/2022 4:00:21 PM |
Analysts calling for 24-26$ target | PennyPusher786 | investorshub | 11/08/2022 3:19:40 PM |
This may just rise all day with that | PennyPusher786 | investorshub | 11/08/2022 3:03:10 PM |
News, Short Squeeze, Breakout and More Instantly...
Ocuphire Pharma Inc Com Company Name:
OCUP Stock Symbol:
NASDAQ Market:
FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that Daniel Su, ...
LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire’s Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for t...
FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. comme...